Severity of Megakaryocyte-Driven Osteosclerosis in Mpig6b-Deficient Mice Is Sex-Linked

Mariya Stavnichuk1,2, Josephine T Tauer2,3, Zoltan Nagy4

  • 1Department of Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada.

Insights

Loss-of-function mutations in MPIG6B cause myelofibrosis and osteosclerosis. Estrogen exacerbates this condition in female mice, highlighting its role in megakaryocyte-driven bone disease.

Area of Science:

  • Hematology
  • Bone Biology
  • Endocrinology

Background:

  • Chronic myelofibrosis is linked to abnormal megakaryocyte function and osteosclerosis.
  • Mutations in MPIG6B (encoding G6b-B) cause macrothrombocytopenia and myelofibrosis.
  • The role of sex hormones in MPIG6B-associated osteosclerosis is not well understood.

Purpose of the Study:

  • To investigate osteosclerosis development in Mpig6b null mice.
  • To determine the influence of sex hormones on MPIG6B-associated osteosclerosis.

Main Methods:

  • Comparative analysis of Mpig6b-/- mice (male and female) using micro-computed tomography (microCT).
  • Surgical manipulation: ovariectomy and orchiectomy in Mpig6b-/- mice.
  • Assessment of bone marrow cellularity, megakaryocyte number, and spleen weight.

Main Results:

  • Mpig6b-/- mice exhibit elevated megakaryocytes and macrothrombocytopenia.
  • Female Mpig6b-/- mice develop progressive osteosclerosis and splenomegaly.
  • Ovariectomy prevents osteosclerosis in females, implicating estrogen as a key factor.

Conclusions:

  • Estrogen significantly contributes to the severity of megakaryocyte-driven osteosclerosis in Mpig6b-/- mice.
  • MPIG6B deficiency leads to sex-specific differences in myelofibrosis and osteosclerosis progression.
  • Targeting estrogen may offer therapeutic potential for MPIG6B-related bone complications.